Novel nitro-oxy derivatives of celecoxib for the regulation of colon cancer cell growth

Chemico-Biological Interactions

Volumn 182, Issue 2-3, 2009, Pages 183-190

  Bozzo, Francesca ^a   Bassignana, Andrea ^a   Lazzarato, Loretta ^a   Boschi, Donatella ^a   Gasco, Alberto ^a   Bocca, Claudia ^a   Miglietta, Antonella ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Catenin E cadherin; Colon cancer; Cyclooxygenase 2; NO celecoxib; Proliferation

Indexed keywords

BETA CATENIN; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; NITROOXYCELECOXIB DERIVATIVE; UNCLASSIFIED DRUG; UVOMORULIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CELL STRAIN HT29; CELL SURVIVAL; COLON CANCER; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; SIGNAL TRANSDUCTION;

BETA CATENIN; CADHERINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; HUMANS; PYRAZOLES; SULFONAMIDES;

ANIMALIA;

EID: 70350129705     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2009.08.006     Document Type: Article

References (57)

1. Müller-Decker K., and Fürstenberger G. The cyclooxygenase-2-mediated prostaglandin signaling is causally related to epithelial carcinogenesis. Mol. Carcinog. 46 (2007) 705-710
2. Moon R.T., Kohn A.D., De Ferrari G.V., and Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat. Rev. Genet. 5 (2004) 691-701
3. Hollingshead H.E., Borland M.G., Billin A.N., Willson T.M., Gonzalez F.J., and Peters J.M. Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms. Carcinogenesis 29 (2008) 169-176
4. Wang D., and Dubois R.N. Prostaglandins and cancer. Gut 55 (2006) 115-122
5. Castellone M.D., Teramoto H., Williams B.O., Druey K.M., and Gutkind J.S. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 310 (2005) 1504-1510
6. Aoki K., and Taketo M.M. Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene. J. Cell. Sci. 120 (2007) 3327-3335
7. Karim R., Tse G., Putti T., Scolyer R., and Lee S. The significance of the Wnt pathway in the pathology of human cancers. Pathology 36 (2004) 120-128
8. Mareel M., and Leroy A. Clinical, cellular, and molecular aspects of cancer invasion. Physiol. Rev. 83 (2003) 337-376
9. Cavallaro U., and Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat. Rev. Cancer 4 (2004) 118-132
10. Truant S.C., Gouyer V.P., Leteurtre E.A., Zerimech F., Huet G.M., and Pruvot F.R. E-cadherin and beta-catenin mRNA levels throughout colon cancer progression. J. Surg. Res. 150 (2008) 212-218
11. Bellovin D.I., Bates R.C., Muzikansky A., Rimm D.L., and Mercurio A.M. Altered localization of p120 catenin during epithelial to mesenchymal transition of colon carcinoma is prognostic for aggressive disease. Cancer Res. 65 (2005) 10938-10945
12. Antonakopoulos N., and Karamanolis D.G. The role of NSAIDs in colon cancer prevention. Hepatogastroenterology 54 (2007) 1694-1700
13. Guadagni F., Ferroni P., Palmirotta R., Del Monte G., Formica V., and Roselli M. Non-steroidal anti-inflammatory drugs in cancer prevention and therapy. Anticancer Res. 27 (2007) 3147-3162
14. Shiff S.J., and Rigas B. The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs). J. Exp. Med. 190 (1999) 445-450
15. Soh J.W., and Weinstein I.B. Role of COX-independent targets of NSAIDs and related compounds in cancer prevention and treatment. Prog. Exp. Tumor Res. 37 (2003) 261-285
16. Caporali R., and Montecucco C. Cardiovascular effects of coxibs. Lupus 14 (2005) 785-788
17. Motsko S.P., Rascati K.L., Busti A.J., Wilson J.P., Barner J.C., Lawson K.A., and Worchel J. Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. Drug Saf. 29 (2006) 621-632
18. Tegeder I., and Geisslinger G. Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?. Naunyn Schmiedebergs Arch. Pharmacol. 373 (2006) 1-17
19. Brophy J.M. Cardiovascular effects of cyclooxygenase-2 inhibitors. Curr. Opin. Gastroenterol. 23 (2007) 617-624
20. Dogné J.M., Supuran C.T., and Pratico D. Adverse cardiovascular effects of the coxibs. J. Med. Chem. 48 (2005) 2251-2257
21. Antman E.M., DeMets D., and Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation 112 (2005) 759-770
22. Wallace J.L., and Del Soldato P. The therapeutic potential of NO-NSAIDs. Fundam. Clin. Pharmacol. 17 (2003) 11-20
23. Rigas B., and Williams J.L. NO-releasing NSAIDs and colon cancer chemoprevention: a promising novel approach. Int. J. Oncol. 20 (2002) 885-890
24. Chiroli V., Benedini F., Ongini E., and Del Soldato P. Nitric oxide-donating non-steroidal anti-inflammatory drugs: the case of nitroderivatives of aspirin. Eur. J. Med. Chem. 38 (2003) 441-446
25. Kashfi K., and Rigas B. The mechanism of action of nitric oxide-donating aspirin. Biochem. Biophys. Res. Commun. 358 (2007) 1096-1101
26. Hulsman N., Medema J.P., Bos C., Jongejan A., Leurs R., Smith M.J., de Esch I.J., Richel D., and Wijtmans M. Chemical insights in the concept of hybrid drugs: the antitumor effect of nitric oxide-donating aspirin involves a quinone methide but not nitric oxide nor aspirin. J. Med. Chem. 50 (2007) 2424-2431
27. Ranatunge R.R., Augustyniak M., Bandarage U.K., Earl R.A., Ellis J.L., Garvey D.S., Janero D.R., Letts L.G., Martino A.M., Murty M.G., Richardson S.K., Schroeder J.D., Shumway M.J., Tam S.W., Trocha A.M., and Young D.V. Synthesis and selective cyclooxygenase-2 inhibitory activity of a series of novel, nitric oxide donor-containing pyrazoles. J. Med. Chem. 47 (2004) 2180-2193
28. Chegaev K., Lazzarato L., Tosco P., Cena C., Marini E., Rolando B., Carrupt P.A., Fruttero R., and Gasco A. NO-donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties. J. Med. Chem. 50 (2007) 1449-1457
29. Velazquez C., Rao P.N.P., McDonald R., and Knaus E.E. Synthesis and biological evaluation of 3,4-diphenyl-1,2,5-oxadiazole-2-oxides and 3,4-diphenyl-1,2,5-oxadiazoles as potential hybrid COX-2 inhibitor/nitric oxide donor agents. Bioorg. Med. Chem. 13 (2005) 2749-2757
30. Del Grosso E., Boschi D., Lazzarato L., Cena C., Di Stilo A., Fruttero R., Moro S., and Gasco A. The furoxan system: design of selective nitric oxide (NO) donor inhibitors of COX-2 endowed with anti-aggregatory and vasodilating activities. Chem. Biodivers. 2 (2005) 886-900
31. Abdellatif K.R.A., Chowdhury M.A., Dong Y., Velazquez C., Das D., Suresh M.R., and Knaus E.E. Diazen-1ium-1,2-diolated nitric oxide donor ester prodrugs of 5-(4-hydroxymethylphenyl)-1-(4-aminosulfonylphenyl)-3-trifluoromethyl-1H-pyrazole and its methanesulfonyl analog: synthesis, biological evaluation and nitric oxide release studies. Bioorg. Med. Chem. 16 (2008) 9694-9698
32. Boschi D., Lazzarato L., Rolando B., Filieri A., Cena C., Di Stilo A., Fruttero R., and Gasco A. Nitrooxymethyl substituted analogues of celecoxib: synthesis and pharmacological characterization. Chem. Biodivers. 6 (2009) 369-379
33. Smith M.L., Hawcroft G., and Hull M.A. The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. Eur. J. Cancer 36 (2000) 664-674
34. Psaty B.M., and Potter J.D. Risks and benefits of celecoxib to prevent recurrent adenomas. N. Engl. J. Med. 355 (2006) 950-952
35. Cahlin C., Lönnroth C., Arvidsson A., Nordgren S., and Lundholm K. Growth associated proteins in tumor cells and stroma related to disease progression of colon cancer accounting for tumor tissue PGE2 content. Int. J. Oncol. 32 (2008) 909-918
36. Steinbach G., Lynch P.M., Phillips R.K., Wallace M.H., Hawk E., Gordon G.B., Wakabayashi N., Saunders B., Shen Y., Fujimura T., Su L.K., and Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342 (2000) 1946-1952
37. Chun K.S., Kim S.H., Song Y.S., and Surh Y.J. Celecoxib inhibits phorbol ester-induced expression of COX-2 and activation of AP-1 and p38 MAP kinase in mouse skin. Carcinogenesis 25 (2004) 713-722
38. Steffel J., Hermann M., Greutert H., Gay S., Luscher T.F., Ruschitzka F., and Tunner F.C. Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation. Circulation 111 (2005) 1685-1689
39. Gallicchio M., Rosa A.C., Dianzani C., Brucato L., Benetti E., Collino M., and Fantozzi R. Celecoxib decreases expression of the adhesion molecules ICAM-1 and VCAM-1 in a colon cancer cell line (HT-29). Br. J. Pharmacol. 153 (2008) 870-878
40. Pozzi A., Yan X., Macias-Perez I., Wei S., Hata A.N., Breyer R.M., Morrow J.D., and Capdevila J.H. Colon carcinoma cell growth is associated with prostaglandin E2/EP4 receptor-evoked ERK activation. J. Biol. Chem. 279 (2004) 29797-29804
41. Wada T., and Penninger J.M. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 23 (2004) 2838-2849
42. Sun Y., and Sinicrope F.A. Selective inhibitors of MEK1/ERK44/42 and p38 mitogen-activated protein kinases potentiate apoptosis induction by sulindac sulfide in human colon carcinoma cells. Mol. Cancer Ther. 4 (2005) 51-59
43. Tuynman J.B., Vermeulen L., Boon E.M., Kemper K., Zwinderman A.H., Peppelenbosch M.P., and Richel D.J. Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer. Cancer Res. 68 (2008) 1213-1220
44. Maier T.J., Janssen A., Schmidt R., Geisslinger G., and Grösch S. Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. FASEB J. 19 (2005) 1353-1355
45. Julkunen K., Mäkinen K., Kärjä V., Kosma V.M., and Eskelinen M. Alpha-, beta- and chi-catenin expression in human pancreatic cancer. Anticancer Res. 23 (2003) 5043-5047
46. Chesire D.R., and Isaacs W.B. Beta-catenin signaling in prostate cancer: an early perspective. Endocr. Relat. Cancer 10 (2003) 537-560
47. Buhmeida A., Elzagheid A., Algars A., Collan Y., Syrjänen K., and Pyrhönen S. Expression of the cell-cell adhesion molecule beta-catenin in colorectal carcinomas and their metastases. APMIS 116 (2008) 1-9
48. Noda M., Tatsumi Y., Tomizawa M., Takama T., Mitsufuji S., Sugihara H., Kashima K., and Hattori T. Effects of etodolac, a selective cyclooxygenase-2 inhibitor, on the expression of E-cadherin-catenin complexes in gastrointestinal cell lines. J. Gastroenterol. 37 (2002) 896-904
49. Okamoto A., Shirakawa T., Bito T., Shigemura K., Hamada K., Gotoh A., Fujisawa M., and Kawabata M. Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo. Urology 71 (2008) 156-160
50. Park B.H., Vogelstein B., and Kinzler K.W. Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 2598-2603
51. Marin H.E., Peraza M.A., Billin A.N., Willson T.M., Ward J.M., Kennett M.J., Gonzalez F.J., and Peters J.M. Ligand activation of peroxisome proliferator-activated receptor beta inhibits colon carcinogenesis. Cancer Res. 66 (2006) 4394-4401
52. Gupta R.A., Wang D., Katkuri S., Wang H., Dey S.K., and DuBois R.N. Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth. Nat. Med. 10 (2004) 245-247
53. Wang D., Wang H., Shi Q., Katkuri S., Walhi W., Desvergne B., Das S.K., Dey S.K., and DuBois R.N. Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell. 6 (2004) 285-295
54. Kozoni V., Rosenberg T., and Rigas B. Development of novel agents based on nitric oxide for the control of colon cancer. Acta Pharmacol. Sin. 28 (2007) 1429-1433
55. Rigas B. Novel agents for cancer prevention based on nitric oxide. Biochem. Soc. Trans. 35 (2007) 1364-1368
56. Stockinger A., Eger A., Wolf J., Beug H., and Foisner R. E-cadherin regulates cell growth by modulating proliferation-dependent beta-catenin transcriptional activity. J. Cell Biol. 154 (2001) 1185-1196
57. George S.J., and Dwivedi A. MMPs, cadherins, and cell proliferation. Trends Cardiovasc. Med. 14 (2004) 100-105